369 related articles for article (PubMed ID: 23775898)
1. Targets for botulinum toxin in the lower urinary tract.
Cruz F
Neurourol Urodyn; 2014 Jan; 33(1):31-8. PubMed ID: 23775898
[TBL] [Abstract][Full Text] [Related]
2. Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A.
Dolly JO; Lawrence GW
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S14-20. PubMed ID: 25042137
[TBL] [Abstract][Full Text] [Related]
3. Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome.
Liu HT; Chen SH; Chancellor MB; Kuo HC
PLoS One; 2015; 10(8):e0134803. PubMed ID: 26241848
[TBL] [Abstract][Full Text] [Related]
4. Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.
Hanna-Mitchell AT; Wolf-Johnston AS; Barrick SR; Kanai AJ; Chancellor MB; de Groat WC; Birder LA
Neurourol Urodyn; 2015 Jan; 34(1):79-84. PubMed ID: 24167028
[TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
Chen SF; Chang CH; Kuo HC
Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
[TBL] [Abstract][Full Text] [Related]
6. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers.
Lawrence GW; Aoki KR; Dolly JO
J Pharmacol Exp Ther; 2010 Sep; 334(3):1080-6. PubMed ID: 20576797
[TBL] [Abstract][Full Text] [Related]
7. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.
Apostolidis A; Rahnama'i MS; Fry C; Dmochowski R; Sahai A
Neurourol Urodyn; 2016 Feb; 35(2):293-8. PubMed ID: 26872570
[TBL] [Abstract][Full Text] [Related]
8. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action.
Coelho A; Cruz F; Cruz CD; Avelino A
Eur Urol; 2012 Jun; 61(6):1178-84. PubMed ID: 22306320
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury.
Smith CP; Gangitano DA; Munoz A; Salas NA; Boone TB; Aoki KR; Francis J; Somogyi GT
Neurochem Int; 2008 May; 52(6):1068-75. PubMed ID: 18187233
[TBL] [Abstract][Full Text] [Related]
10. Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction-induced detrusor overactivity.
Ha US; Park EY; Kim JC
Urology; 2011 Sep; 78(3):721.e1-721.e6. PubMed ID: 21782224
[TBL] [Abstract][Full Text] [Related]
11. Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves.
Chuang YC; Huang TL; Tyagi P; Huang CC
J Urol; 2016 Aug; 196(2):599-608. PubMed ID: 26724396
[TBL] [Abstract][Full Text] [Related]
12. Effect of botulinum neurotoxin on the urinary bladder: novel insights on mechanism of action.
Vianello A; Proietti S; Giannantoni A
Minerva Urol Nefrol; 2010 Sep; 62(3):259-71. PubMed ID: 20940695
[TBL] [Abstract][Full Text] [Related]
13. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Nambiar A; Lucas M
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
Lin YH; Chiang BJ; Liao CH
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085522
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.
Kanai A; Zabbarova I; Oefelein M; Radziszewski P; Ikeda Y; Andersson KE
Neurourol Urodyn; 2012 Mar; 31(3):300-8. PubMed ID: 22275187
[TBL] [Abstract][Full Text] [Related]
16. Effect of onabotulinumtoxinA on intramural parasympathetic ganglia: an experimental study in the guinea pig bladder.
Coelho A; Cruz F; Cruz CD; Avelino A
J Urol; 2012 Mar; 187(3):1121-6. PubMed ID: 22266001
[TBL] [Abstract][Full Text] [Related]
17. Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.
Chancellor MB; Fowler CJ; Apostolidis A; de Groat WC; Smith CP; Somogyi GT; Aoki KR
Nat Clin Pract Urol; 2008 Jun; 5(6):319-28. PubMed ID: 18461049
[TBL] [Abstract][Full Text] [Related]
18. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A.
Smith CP; Vemulakonda VM; Kiss S; Boone TB; Somogyi GT
Neurochem Int; 2005 Sep; 47(4):291-7. PubMed ID: 15970360
[TBL] [Abstract][Full Text] [Related]
19. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
Tubaro A; Puccini F; De Nunzio C
Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
[TBL] [Abstract][Full Text] [Related]
20. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
